替非罗班和abciximab展览等效抗血小板疗效的实验模型支架在健康志愿者和冠状动脉疾病患者。
文章的细节
-
引用
复制到剪贴板 -
Amoroso G, van Boven AJ,范Veldhuisen DJ, Tio RA, Balje-Volkers CP, Petronio, van Oeveren W
替非罗班和abciximab展览等效抗血小板疗效的实验模型支架在健康志愿者和冠状动脉疾病患者。
J Cardiovasc杂志。2001年10月,38 (4):633 - 41。
- PubMed ID
-
11588534 (在PubMed]
- 文摘
-
血小板沉积和聚合是冠状动脉支架的急性血栓形成的主要决定因素。我们旨在比较不同治疗方法的抗血小板疗效——糖蛋白(Gp) IIb / iii a抑制剂和传统antiaggregants支架——在一个实验模型。冠状动脉疾病患者血样来自(n = 15)和健康志愿者(n = 8)和孵化与替非罗班(2.0 microg /毫升),abciximab (3.0 microg /毫升),吲哚美辛(15 microg /毫升),或者是盐水。在全血血小板腺苷diphosphate-induced聚合所有组评估。血还测试了在实验循环模型中含有金属探测器,在血小板沉积在剪切流条件下评估通过使platelet-specific (anti-GpIIIa和Ib)抗体。替非罗班abciximab,与吲哚美辛和不治疗相比,显著降低血小板聚集(0,0,4和3任意单元(AU),分别;p < 0.001), anti-GpIIIa(2.25, 1.83, 11.24,和13.42计数每秒(cps) /毫克,分别;p < 0.001), anti-GpIb绑定(0.61,0.61,1.00,和1.83 cps /毫克,分别;p < 0.001)。Anti-GpIIIa和anti-GpIb绑定显著相关(R = 0.36; p < 0.01). Patients showed a higher anti-GpIIIa, but not anti-GpIb binding, than controls (8.43 versus 3.33 cps/mg; p < 0.01), irrespective of treatment. In conclusion, eptifibatide and abciximab show equivalent in vitro antiplatelet efficacy, superior to that of indomethacin. Given the occurrence of GpIIb/IIIa platelet overexpression in the course of coronary artery disease, an extended use of GpIIb/IIIa inhibitors may be proposed to prevent acute thrombosis during routine coronary stenting.